LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacterial Panel Detects Stool Pathogens from Swabs

By LabMedica International staff writers
Posted on 25 Apr 2017
Print article
Image: A Polymerase Chain Reaction (PCR) processing card for the BD Max molecular diagnostics platform (Photo courtesy of BD Diagnostic Systems).
Image: A Polymerase Chain Reaction (PCR) processing card for the BD Max molecular diagnostics platform (Photo courtesy of BD Diagnostic Systems).
Repeated bouts of diarrhea and persistent diarrheal disease disrupt intestinal function and absorption, making diarrheal disease a leading cause of malnutrition in children less than 5 years of age. Importantly, diarrheal disease is both treatable when correctly diagnosed and preventable via proper infection control measures.

In the USA, Salmonella, Campylobacter, Shigella, and Shiga toxin-producing Escherichia coli are the most common bacterial pathogens, and they are usually associated with foodborne illnesses. Identifying the cause of diarrhea is important for the treatment of patients and for public health intervention through outbreak management.

Microbiologists at Cincinnati Children’s Hospital Medical Center collected 272 sequential rectal swab samples from August 2015 to December 2015 for conventional bacterial culture and Shiga Toxin testing, as standard of care. The team evaluated a molecular test to detect pathogens from the stool swabs. Discrepant test results were resolved using Verigene Enteric Pathogens Nucleic Acid Test (EP) on the Verigene System.

The molecular test evaluated was the BD MAX Enteric Bacterial Panel (BDM-EBP), which is designed and FDA-cleared to detect Salmonella, Shigella, Campylobacter, and Shiga toxin genes stx1/2 from stool samples. There were also 36 challenge samples (13 Salmonella spp., three Shigella spp., 10 Campylobacter spp., and 10 Shiga toxin positive Escherichia coli) that were tested using reference strains and previous patient isolates diluted to103-104 cfu/mL in saline then added to Sample Buffer Tube (SBT) with negative stool matrix delivered via a swab.

The scientists found that from a total of 272 rectal swab specimens that were evaluated, 89 were positive by culture and/or MAX EBP. All discrepant results were BDM-EBP positive and culture negative. There were 21/31 (68%) of the apparent false positive BDM-EBP discrepant results resolved as positive with Nanosphere’s Verigene EP. They reported that 8.8% of the patient samples did not initially yield a result on the BDM-System. Upon repeat, half of the problematic samples resolved, and 4.4% of the total specimen tested did not yield a result. All organisms in the challenge samples were detected.

The authors concluded that although stool is the optimal specimen for identifying enteric bacterial pathogens, polymerase chain reaction (PCR) from swabs is more sensitive than culture from swabs, and rectal swabs can be used for testing with BDM-EBP for detection of Salmonella spp., Shigella spp., Campylobacter spp., and Shiga toxin 1 and 2 genes. Additionally, BDM –EBP PCR results are available 34 to 47 hours sooner that with conventional cultures from rectal swabs. The study was published on April 8, 2017, in the journal BMC Clinical Pathology.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.